STOCK TITAN
  1. Home
  2. News
  3. BTAI

BioXcel Therapeutics Inc - BTAI STOCK NEWS

Welcome to our dedicated news page for BioXcel Therapeutics (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on BioXcel Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioXcel Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioXcel Therapeutics's position in the market.

News
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
Rhea-AI Summary
BioXcel Therapeutics, Inc. announces the issuance of a new patent for the treatment of agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form. This strengthens the company's strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients. The patent is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment, patent term extension, and terminal disclaimers. Additionally, the company has received an issue notification for another patent related to the treatment of agitation associated with schizophrenia or bipolar disorder through oromucosal administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.24%
Tags
none
-
News
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to review BXCL502 and other potential emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss BXCL502 as a potential treatment for chronic agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid withdrawal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
News
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announces the promotion of Vincent J. O’Neill, M.D., to Executive Vice President, Chief of Product Development and Medical Officer, and the appointment of Rajiv Patni, M.D., as Strategic Clinical Advisor to the CEO and Board of Directors. The company emphasizes a strategic reprioritization focused on advancing late-stage clinical programs and emerging pipeline candidates. O’Neill's promotion and Patni's appointment aim to strengthen clinical leadership in line with the prioritization of late-stage TRANQUILITY and SERENITY III programs for BXCL501’s potential use to treat Alzheimer’s, bipolar disorder, and schizophrenia-related agitation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
clinical trial
News
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to discuss BXCL502, a potential treatment for chronic agitation in dementia, along with other emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid withdrawal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences
-
News
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced plans to conduct Phase 3 trials of BXCL501 in the at-home setting for the TRANQUILITY program, targeting the acute treatment of agitation associated with dementia due to probable Alzheimer’s disease. The FDA's recommendation for a Phase 3 trial aligns with the Company's plans. The company also provided an update on strategic financing activities and reported its financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.41%
Tags
earnings clinical trial
-
News
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype. The median overall survival was 15.5 months with BXCL701 + KEYTRUDA, compared to 9.6 months with checkpoint inhibitor monotherapy, with a 59% one-year survival rate. Median progression-free survival was 4.2 months with BXCL701 + KEYTRUDA, compared to 2.1 months with checkpoint inhibitor monotherapy. The company plans to determine program development path following end of Phase 2 meeting with FDA scheduled for December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
clinical trial
News
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
Rhea-AI Summary
BioXcel Therapeutics provides an update on the NIDA-funded trial evaluating BXCL501 as a potential treatment for opioid use disorder. The trial aims to enroll 160 patients exposed to fentanyl and/or fentanyl adulterated with xylazine. Columbia University has been asked to add a fourth site to target trial completion in 2024. BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
-
News
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
BioXcel Therapeutics, Inc. will release its Q3 2023 financial results on November 14, 2023. The management team will host a conference call and webcast at 8:00 AM ET to discuss the results and provide a general business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences earnings
-
News
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services
Rhea-AI Summary
BioXcel Therapeutics announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent and product-specific J-Code for IGALMI™ (dexmedetomidine) sublingual film, effective January 1, 2024. The J-code will simplify the reimbursement process and facilitate additional patient access to the treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.68%
Tags
none
News
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site
Rhea-AI Summary
BioXcel Therapeutics announces positive findings from independent audit of TRANQUILITY II trial data
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.94%
Tags
clinical trial
Stock BTAI logo
BioXcel Therapeutics Inc

Nasdaq:BTAI

BTAI Rankings

#4412 Ranked by Market Cap
#5252 Ranked by Stock Gains
N/A Ranked by Dividends

BTAI Stock Data

81.95M
21.69M
27.01%
28.51%
8.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New Haven

About BTAI

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.